



## **Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference**

January 2, 2020

CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at [www.editasmedicine.com](http://www.editasmedicine.com). An archived replay will be available for approximately 30 days following the presentation.

### **About Editas Medicine**

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit [www.editasmedicine.com](http://www.editasmedicine.com).

### **Contacts:**

#### **Investors**

Mark Mullikin  
(617) 401-9083  
[mark.mullikin@editasmed.com](mailto:mark.mullikin@editasmed.com)

#### **Media**

Cristi Barnett  
(617) 401-0113  
[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)



Source: Editas Medicine, Inc.